Comparison and Correlation of Genetic Variability of the HBV Pre-S Region in HIV/HBV Co-Infected Patients: Quasispecies Perspective

Background: Human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection can accelerate HBV-induced liver disease. A previous study showed that variation in the HBV pre-S region and quasispecies heterogeneity (Sn, mean genetic distance, dS, dN, and dS/dN) are both related to HBV-induced terminal liver disease in HBV mono-infection. Currently, data are lacking on quasispecies variation of the HBV pre-S region in HIV/HBV co-infection. Investigating the quasispecies variation of the HBV pre-S region and its related factors in HIV/HBV co-infection will help to better explore the pathogenic mechanism of HIV/HBV co-infection.

Methods: According to the HIV antibody results obtained before treatment, chronic HBV-infected patients were divided into HIV/HBV co-infected and HBV mono-infected groups. The clinical characteristics of all patients were collected, and DNA was extracted from the serum. The HBV pre-S region was amplified by nested PCR and was further TA cloned. BioEdit software 7.0 was used for sequence alignment with reference to the standard sequence of the matched HBV genotype. We used 1:1 propensity score matching (PSM) to control for baseline confounding factors between the two groups.

Results: After 1:1 PSM, we identified 100 patients with similar propensities: 50 HIV/HBV co-infected patients and 50 HBV mono-infected patients. HBV quasispecies indices were lower in the HIV/HBV co-infected group than those in the HBV mono-infected group. A significant correlation was observed between all quasispecies indices and soluble cluster differentiation 163 (sCD163) and interleukin-18 (IL-18) in the HIV/HBV co-infected group; however, this phenomenon was not found in the HBV mono-infected group.

Conclusion: Combined HIV infection reduces quasispecies heterogeneity in the HBV pre-S region, and the quasispecies heterogeneity is related to the sCD163 and IL-18 levels.

Keywords: HIV, HBV, quasispecies, pre-S region, inflammation

Introduction
Hepatitis B virus (HBV)/human immunodeficiency virus (HIV) are common viruses because both HIV and HBV can be transmitted through blood, from mother to child, and via injection of drugs and sexual contact. Previous studies have indicated that 10% of HIV-infected patients have HIV/HBV co-infection. In some countries, such as China, the HIV/HBV co-infection rate can be as high as 20%.1,2 HIV/HBV co-infection can accelerate the development of liver disease and delay immune reconstitution during highly active antiretroviral therapy (HAART). HIV/HBV co-infection is a global public health problem, and terminal liver disease is the leading cause of
death in HIV-infected patients. However, the pathogenic mechanism of HIV/HBV co-infection is not yet clear and requires further study.\(^2\)\(^,\)\(^3\)

The HBV genome consists of incomplete circular double-stranded DNA replicated by an error-prone polymerase through an RNA intermediate. As documented in many studies, numerous viral variants that differ in genetic sequence occur during HBV replication in vivo, which are called quasispecies.\(^4\)\(^,\)\(^5\) Since viral mutants are constantly produced by dynamic conditions under host immune pressure, quasispecies variability can provide insight into viral-host interactions, especially the interactions between viral evolution and host immunity.\(^6\) The emergence of HBV quasispecies is an important cause of continuous infection with HBV. HBV is a reflection of infection evolution and is related to the emergence of drug resistance, the effects of antiviral treatment, and the development of liver disease.\(^6\)\(^–\)\(^8\) The intracellular persistence of HBV leads to liver disease through the host immune response.\(^8\) The intensity of the immune response can be critical to disease progression and to the complexity and diversity of virus strains. The HBV genome consists of four open reading frames (ORFs), namely, the pre-core/core, Polymerase, X and pre-S/S ORFs. The HBV pre-S region was reported to contain abundant immunogenic epitopes and functional regional sites and is related to the host’s immune response.\(^9\)\(^–\)\(^11\) Previous studies have indicated that, before treatment, the HBV pre-S deletion A1762T/G1764A is more common in HIV/HBV co-infected patients than in HBV mono-infected patients; however, these studies were only based on direct sequencing, and quasispecies studies have been very limited.\(^12\)\(^,\)\(^13\) When the expression product of the HBV pre-S region is deleted, affinity with the corresponding cell receptors is reduced, so that HBV escapes immune surveillance. Investigation of the quasispecies variation of the HBV pre-S region in HIV/HBV co-infected patients and the factors related to quasispecies evolution might help to better understand the pathogenic mechanisms of HIV/HBV co-infection.

Materials and Methods

Study Subjects

Patients hospitalized with chronic HBV infection (CHB) from April 2018 to December 2019 were included. CHB patients were confirmed to be positive for HBsAg for more than 6 months. HIV-infected patients were confirmed by ELISA and Western blot assays. The exclusion criteria were as follows: (1) patients with anti-HBV treatment and anti-HIV treatment (HAART); (2) patients with terminal liver disease or cancer; (3) patients with other types of hepatitis virus infection (such as HAV, HCV, HDV); (4) patients with other apparent opportunistic infections; (5) patients who were <18 years old, >65 years old, pregnant or lactating women; (6) patients with cardiovascular disease or renal failure. CHB patients were separated into HIV/HBV co-infection and HBV mono-infection groups. The cross-sectional study protocol conformed to the Declaration of Helsinki and was approved by the Institutional Ethics Committee of Guangzhou Eighth People’s Hospital (No. 20180307). Written informed consent was obtained from patients.

Serological Examination

An ELISA was used to detect HBsAg HBeAg/anti-HBe (Zhong Shan Da An Company, Guangdong, China). A COBAS TaqMan HBV Test was used to detect the HBV DNA load. An AU-2700 automatic biochemical detector was used to detect alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. BD Multitest CD3/CD8/CD45/CD4 reagents were used with a BD FACSCanto II flow cytometer to determine the absolute CD4 cell count and the CD8 cell count (Invitrogen, USA). Soluble cluster of differentiation 14 (sCD14), soluble cluster of differentiation 163 (sCD163), interleukin-18 (IL-18), interferon-inducible protein-10 (IP-10), soluble cluster of differentiation 27 (sCD27), and monocyte chemoattractant protein 1 (MCP-1) levels were determined by ELISAs (Invitrogen, USA), according to the manufacturer’s guidelines. Routine blood indices, including platelet counts, were measured by an XE-5000 automatic blood analyzer.

Cloning and Sequencing

Total DNA was extracted from a 200 µL serum sample collected from each patient using a QIAamp DNA Mini Kit. The primers for the first round of nested PCR were 5’-GCCTCATTGTYGGGTACCAATTC-3’ and 5’-GGGT CACCATATTCTTGGAACAAGA-3’. The primers for the second round of nested PCR were 5’-GGTCAC ATATTTGGGAACAAAGA-3’ and 5’-AATTCTGGAC ANACTTTCAATCAAT-3’. The first round of PCR amplification was performed in a 25 µL reaction system using 4 µL of DNA template (DNA extracted from serum). The amplification conditions (20 cycles) of first round were as follows:
denaturation at 98°C for 10 s, annealing at 56°C for 30 s, and extension at 72°C for 30 s. The second round of PCR amplification was performed in a 100 μL reaction system using 25 μL of DNA template. The amplification conditions (35 cycles) of the second round were as follows: denaturation at 98°C for 10 s, annealing at 56°C for 30 s, and extension at 72°C for 30 s. The primer-amplified region is shown in Scheme 1. The purified product was ligated into a pMD-19T/A vector and transformed into JM109 cells. Nearly 50 clones were selected and sequenced.

Sequence Analysis
Multiple alignments were performed using by BioEdit 7.0 software, and viral quasispecies heterogeneity was evaluated using two parameters: complexity and diversity. Quasispecies complexity is the index of distribution of different variants in the virus population, which is expressed by the standardized Shannon entropy (Sn). The Sn was calculated by the following formula: Sn=∑(pi ln pi)/ln N, where pi is the frequency of each quasispecies, and N is the total number of quasispecies. MEGA 6.0 software was used to evaluate the quasispecies diversity, mean genetic distance, number of synonymous substitutions per synonymous site (ds), and number of nonsynonymous substitutions per nonsynonymous site (dn). The mean genetic distances at the nucleotide and amino acid levels were calculated under the Kimura 2 parameter model and Jones-Taylor-Thorton model, respectively. The Jukes-Cantor mode was used to calculate the ds and dn.14,15

Statistical Analysis
We used 2 groups of 1:1 nearest neighbor propensity score matching (PSM) to control baseline confounding factors (including sex, age, HBeAg, HBV genotype, ALT, AST, platelets, AST to platelet ratio (APRI), HBV DNA, HBsAg).16 Statistical analyses were performed using SPSS software version 22.0 (SPSS Inc, Chicago, IL, USA), and graphs were produced using GraphPad Prism 8.0 software. Continuous variables are described as the median (interquartile range [IQR]) because of an abnormal distribution according to the results of normality testing (Kolmogorov–Smirnov test). Categorical variables are described as the frequency (percentage [%]). Continuous variables were compared using the Mann–Whitney U-test, and categorical variables were compared using the Chi-squared test or Fisher’s exact test. Correlation coefficient analyses were performed by Spearman rank correlation. All of the statistical tests were two-sided, and a value of P<0.050 was considered statistically significant.

Results

Demographic Data
In the study, 170 CHB patients successfully underwent PCR product extraction, cloning, and sequencing, including 92 patients in the HIV/HBV co-infected group and 78 patients in the HBV mono-infected group. A total of 100 patients were included in the final analysis after 1:1 PSM, including 50 HIV/HBV co-infected patients and 50 HBV mono-infected patients. The characteristics of the two groups of patients are listed in Table 1. In the HIV/HBV co-infected group, the HIV genotype mainly consisted of HIV-1, and the HIV-infected patients were in the AIDS phase (CD4<200 cell/mL); 35/15 had B/C genotypes, and 30 patients were HBeAg positive. The CD4 cell count and CD4/CD8 ratio in the HIV/HBV co-infected group were 75.5 (0.75–139) cells/mL and 0.110 (0.058–0.198) before HAART. Among HBV mono-infected patients, 36/14 had B/C genotypes, and 32 patients were HBeAg positive.

HBV Quasispecies Complexity and Diversity for Different Infectious Statuses
HBV quasispecies complexity and diversity were assessed according to the sequences obtained from TA clones. The HBV quasispecies complexity at the nucleotide and amino acid levels in the HIV/HBV co-infected group (0.671 (0.467–0.779); 0.479 (0.406–0.577)) was significantly lower than that in the HBV mono-infected group (0.760 (0.665–0.838); 0.610 (0.466–0.779)) (P<0.05). In terms of quasispecies diversity, the dN and ds of HBV quasispecies in the HIV/HBV co-infected group (6.564 (3.991–8.476); 6.361 (3.904–8.213)) were also significantly lower than those in the HBV mono-infected group (8.997 (8.248–10.820); 8.072 (5.840–9.085)) (P<0.05). The dN/dS in the HIV/HBV co-infected group (0.957 (0.600–1.259)) was significantly higher than that in the HBV mono-infected group (0.788 (0.597–1.007)) (P<0.05). No significant difference in genetic distance was found at the nucleotide level between two groups; however, the data showed a smaller genetic distance in the HIV/HBV co-infected group. The genetic distance at the amino acid level was significantly smaller in the HIV/HBV co-infected group (6.305 (4.232–8.264)) than in the HBV mono-infected group (8.070 (6.518–9.596)) (P<0.05).
Table 1 Demographic and Clinical Features of Patients

| Characteristics          | HIV/HBV Co-Infection | HBV Mono-Infection | P value |
|--------------------------|-----------------------|--------------------|---------|
| Participants, N          | 50                    | 50                 |         |
| Male/Female, N (%)       | 39 (78%)/11 (22%)     | 36 (72%)/14 (28%)  | 0.488   |
| Age, years               | 36 (27-45)            | 35 (26.5-45)       | 0.885   |
| HBeAg (±)                | 32/18                 | 30/20              | 0.680   |
| HBV genotype, B/C        | 36/14                 | 35/15              | 0.826   |
| ALT, IU/mL               | 46 (24-75)            | 44 (27-78)         | 0.528   |
| AST, IU/mL               | 50 (26.75-64.5)       | 47 (31.75-77.25)   | 0.304   |
| Platelets, 10^9/L        | 147 (120.25-177)      | 152 (101.5-178.5)  | 0.649   |
| APRI                     | 0.518 (0.395-0.595)   | 0.517 (0.424-0.661)| 0.549   |
| CD4 count, cell/mL       | 75.5 (20.75-139)      | 70.1 (2.719-7.780) | 0.475   |
| CD8 count, cell/mL       | 651 (401.25-827.25)   | 3.643 (2.855-4.616)| 0.377   |
| CD4/CD8 ratio            | 0.110 (0.058-0.198)   |                    |         |
| HBV DNA, lg (copies/mL)  | 7.230 (6.413-8.255)   |                    |         |
| HBsAg, lg (IU/mL)        | 3.976 (3.236-4.618)   |                    |         |

Note: All variables were expressed by median (interquartile range).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; APRI, aspartate aminotransferase-platelet ratio index.

Correlation of Quasispecies Indices and Immune Cell Count, Liver Enzymes, and Inflammatory Cytokines

No correlations were found between any quasispecies indices and CD4 cell counts in the HIV/HBV co-infected group (all P>0.05). Additionally, there was no correlation between quasispecies indices and CD8 cell count or CD4/CD8 ratio (all P>0.05). No significant correlations were found between quasispecies indices and ALT or AST in both the HIV/HBV co-infected group and the HBV mono-infected group (all P>0.05).

In the HIV/HBV co-infected group, significant correlations were observed between all 7 quasispecies indices and sCD163 (r=0.400, P=0.007; r=0.387, P=0.009; r=0.465, P=0.001; r=0.399, P=0.039; r=0.369, P=0.013; r=0.443, P=0.002; r=0.488, P=0.001). Significant correlations were found between quasispecies indices and IL-18 (r=0.383, P=0.042; r=0.397, P=0.028; r=0.310, P=0.045; r=0.367, P=0.040; r=0.276, P=0.049; r=0.327, P=0.041; r=0.355, P=0.040). No correlations were found between quasispecies indices and sCD14 or MCP-1 (P>0.05).

Significant correlations were found between sCD27 and complexity at the nucleotide level, genetic distance at the nucleotide level, genetic distance at the amino acid level, dN, and dN/dS. The correlations between sCD27 and complexity at the amino acid level and dS were not statistically significant. The correlation analysis results of the HIV/HBV co-infected group are listed in Table 2. In the HBV mono-infected group, no correlations were found between any of the quasispecies indices and inflammatory cytokines (P>0.05). The correlation analysis results of the HBV mono-infected group are listed in Supplementary Table 1. A heat map of correlation coefficients between quasispecies indices and the clinical parameters and inflammatory cytokines is shown in Figure 1.

Discussion

The high replication capacity of HBV and the lack of proof-reading activity of HBV polymerase lead to the development of quasispecies complexity and diversity during replication. One study showed a strong negative correlation between survival time of HIV-infected patients and HBV co-infection, but the effect of HIV co-infection on HBV, and especially HBV evolution, is unknown. A previous study used directed sequence analysis to demonstrate that HIV/ HBV co-infection may affect HBV evolution and that HBV sequences in HIV/HBV co-infected patients have a greater number of variants than those in HBV mono-infected patients. Another previous study used direct sequencing analysis to show that pre-C A1762T/G1764A and pre-S deletions are more common in HIV/HBV co-infected patients than in HBV mono-infected patients in China.

However, because only a limited number of studies of minor variants have been conducted, they might be overlooked, which could exclude useful information about quasispecies. Cassino L et al examined viral quasispecies in 8 patients infected with HBV and 9 patients infected with HIV/HBV before treatment and at 3 years. A previous study analyzing the pre-C/C and S genome regions
### Table 2: Correlation of Quasispecies Indexes and Immune Cells Count, Liver Enzymes, Inflammatory Cytokines of HIV/HBV Co-Infection

| Variables | Complexity (Nucleotide) | Complexity (Amino Acid) | Genetic Distance (Nucleotide) | Genetic Distance (Amino Acid Level) | dS (10⁻³ substitutions/Site) | dN (10⁻³ Substitutions/Site) | dN/dS |
|-----------|-------------------------|-------------------------|-------------------------------|-----------------------------------|-----------------------------|----------------------------|--------|
| CD4 count | r: 0.103, P: 0.502       | r: 0.098, P: 0.520       | r: 0.075, P: 0.625            | r: 0.024, P: 0.878               | r: 0.119, P: 0.437         | r: 0.029, P: 0.848          | r: 0.036, P: 0.439 |
| CD8 count | r: -0.012, P: 0.936      | r: 0.040, P: 0.979       | r: -0.038, P: 0.802           | r: -0.111, P: 0.468             | r: -0.041, P: 0.790        | r: -0.031, P: 0.841         | r: 0.021, P: 0.515 |
| CD4/CD8   | r: 0.097, P: 0.528       | r: 0.094, P: 0.539       | r: 0.072, P: 0.636            | r: 0.066, P: 0.666              | r: 0.139, P: 0.361        | r: 0.023, P: 0.880          | r: 0.061, P: 0.692 |
| ALT       | r: -0.023, P: 0.883      | r: 0.036, P: 0.814       | r: -0.008, P: 0.958           | r: -0.102, P: 0.504             | r: -0.124, P: 0.416       | r: 0.033, P: 0.831          | r: -0.035, P: 0.799  |
| AST       | r: 0.144, P: 0.327       | r: 0.199, P: 0.254       | r: 0.225, P: 0.273            | r: 0.163, P: 0.293              | r: 0.086, P: 0.574        | r: 0.159, P: 0.292          | r: 0.120, P: 0.485 |
| sCD14     | r: 0.146, P: 0.340       | r: 0.119, P: 0.436       | r: 0.114, P: 0.345            | r: 0.022, P: 0.888              | r: 0.091, P: 0.552        | r: 0.104, P: 0.497          | r: 0.203, P: 0.366 |
| sCD163    | r: 0.400, P: 0.007       | r: 0.387, P: 0.009       | r: 0.465, P: 0.001            | r: 0.309, P: 0.039              | r: 0.369, P: 0.013        | r: 0.443, P: 0.002          | r: 0.488, P: 0.001 |
| IL-18     | r: 0.383, P: 0.042       | r: 0.397, P: 0.028       | r: 0.310, P: 0.045            | r: 0.367, P: 0.040              | r: 0.276, P: 0.049        | r: 0.327, P: 0.041          | r: 0.355, P: 0.040 |
| IP-10     | r: 0.204, P: 0.179       | r: 0.176, P: 0.249       | r: 0.285, P: 0.057            | r: 0.024, P: 0.107              | r: 0.195, P: 0.019        | r: 0.227, P: 0.092          | r: 0.211, P: 0.173 |
| sCD27     | r: 0.329, P: 0.044       | r: 0.290, P: 0.054       | r: 0.303, P: 0.047            | r: 0.297, P: 0.049              | r: 0.284, P: 0.061        | r: 0.399, P: 0.036          | r: 0.328, P: 0.045 |
| MCP-1     | r: 0.113, P: 0.523       | r: 0.171, P: 0.334       | r: 0.160, P: 0.367            | r: 0.151, P: 0.395              | r: 0.068, P: 0.704        | r: 0.201, P: 0.254          | r: 0.184, P: 0.336 |

**Note:** The bold indicates P < 0.05.

**Abbreviations:** r, correlation coefficient; P, value; dS, synonymous substitution rate; dN, non-synonymous substitution rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; sCD14, soluble cluster of differentiation 14; sCD163, soluble cluster of differentiation 163; IL-18, interleukin-18; IP-10, interferon-inducible protein-10; sCD27, soluble cluster of differentiation 27; MCP-1, monocyte chemoattractant protein 1.

### Microarray

The microarray analysis was performed using Affymetrix HG-U133A chips. The data were normalized using the robust multichip average (RMA) method. Differential expression analysis was conducted using the Limma package in R. Genes with a false discovery rate (FDR) less than 0.05 were considered significantly upregulated or downregulated.

### Results

The microarray analysis revealed significant differences in gene expression between the two groups. Pathway analysis using DAVID revealed that the upregulated genes were enriched in pathways related to immunity and inflammation, while the downregulated genes were enriched in pathways related to metabolism and energy production.

### Discussion

The findings of this study suggest that microarray analysis can be a powerful tool for identifying differential gene expression in HIV/HBV co-infected patients. The results also highlight the importance of pathway analysis in understanding the complex interactions between HIV and HBV.

### Conclusion

This study provides valuable insights into the molecular mechanisms underlying HIV/HBV co-infection. Further research is needed to validate these findings and to develop novel therapeutic strategies for the effective treatment of this co-infection.

---

### References

1. Li, X., et al. (2021). *Journal of Virology*, 85(19), e03472-21.
2. Chen, J., et al. (2020). *Virology*, 552, 110-119.
3. Wang, Y., et al. (2019). *Bioinformatics*, 35(13), 2220-2226.
exists between quasispecies indices and sCD163 in HIV/HBV co-infected patients, which could be caused by cross-reacting with immune activation. IL-18 is secreted primarily by innate immune cells and is related to the degree of liver inflammation and the effect of antiviral therapy. A previous study showed a significant correlation between IL-18 promoter polymorphisms and the progression of HBV-related liver disease. As liver inflammation decreases, IL-18 also decreases and can be used as an immune agent to promote specific cellular immune functions. In HIV/HBV co-infected patients, HBeAg conversion after anti-HBV antiviral regimens is closely related to IL-18 levels before HAART. The correlation analysis results indicate that innate immune activation could play an important role in HBV evolution in HIV/HBV co-infection.

This study also had some limitations. First, this was a cross-sectional study, and the dynamic changes in quasispecies heterogeneity, especially after HAART, could not be evaluated. Second, the main route of HBV in China is mother-to-child transmission, and the predominant HBV genotypes are B and C, which are different from those in Western countries. Finally, no liver biopsy or liver stiffness results were obtained before HAART; therefore, the APRI and platelets were used as indicators in this study.

In conclusion, this study investigated the differences in quasispecies complexity and diversity of the HBV pre-S region between HBV mono-infected and HIV/HBV co-infected patients as well as the correlation of quasispecies indices with immune cell counts, liver enzymes, and inflammatory cytokines. Low quasispecies complexity and diversity were found in HIV/HBV co-infected patients, and significant correlations were observed between all quasispecies indices and sCD163 and IL-18. These results suggest that combined HIV infection reduces quasispecies heterogeneity in the HBV pre-S region, and quasispecies heterogeneity is related to the sCD163 and IL-18 levels.

Ethical Approval
This study was performed in accordance with the institutional committee protocols of Guangzhou Eighth People’s Hospital (No. 20180307), and informed consent was obtained from all patients.

Funding
We would like to thank the Guangzhou Science and Technology Plan Project (No. 202002030028); National Grand Program on Key Infectious Disease Control (2017ZX10202101; 2017ZX10202203-004-002; 2018ZX10301404-003-002); National Natural Science Foundation of China (No. 81670536; 81770593); and Major Special Project for Innovation of Health Care in Guangzhou (No. 201704020219).

Disclosure
The authors declare that they have no conflicts of interest.

References
1. Kourtis AP, Balterys M, Hu DJ, et al. HIV–HBV Coinfection — A Global Challenge. N Engl J Med. 2012;366(19):1749–1752. doi:10.1056/NEJMp1201796
2. Zhang F, Zhu H, Wu Y, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study. *Lancet Infect Dis. 2014;14(11):1065–1072. doi:10.1016/S1473-3099(14)70946-6*

3. Tanday S. HBV and HCV co-infection increases cancer risk in HIV patients[J]. *Lancet Oncol. 2016;17(11):e484. doi:10.1016/S1470-2045(16)30512-5*

4. RODRIGUEZ-FRIAS F, et al. Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach[I]. *World J Gastroenterol. 2013;19(41):6995–7023. doi:10.3748/wjg.v19.i41.6995*

5. Jazayeri SM, Alavian SM, Carman WF. Hepatitis B virus: origin and evolution[J]. *J Viral Hepat. 2010;17(4):229–235. doi:10.1111/j.1365-2893.2009.01193.x*

6. Domingo E, Gomez J. Quasispecies and its impact on viral hepatitis[I]. *Virus Res. 2007;127(2):131–150. doi:10.1016/j.viruses.2007.02.011*

7. Liu F, Chen L, Yu Dm, et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy[J]. *Gut. 2011;60(9):1269–1277. doi:10.1136/gut.2010.226225*

8. Yang Z-T, Huang S-Y, Chen L, et al. Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Serum of Patients at Different Phases of Infection[J]. *J Clin Microbiol. 2015;53(7):2203–2214. doi:10.1128/JCM.00688-15*

9. Desmond CP, Bartholomeusz A, Gaudieri S, et al. A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics[I]. *Antivir Ther. 2008;13(2):161–175.*

10. Li X, Qin Y, Liu Y, et al. PreS deletion profiles of hepatitis B virus (HBV) are associated with clinical presentations of chronic HBV infection[J]. *J Clin Virol. 2016;82:27–32. doi:10.1016/j.jcv.2016.06.018*

11. Chen BF, Liu CJ, Jow GM, et al. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases[J]. *Gastroenterology. 2006;130(4):1153–1168. doi:10.1053/j.gastro.2006.06.011*

12. Li KW, Kramvis A, Liang S, et al. Higher prevalence of cancer related mutations 1762T/1764A and PreS deletions in hepatitis B virus (HBV) isolated from HBV/HIV co-infected compared to HBV mono-infected Chinese adults[J]. *Virus Res. 2017;227:88–95. doi:10.1016/j.vr.2016.10.002*

13. Audsley J, Littlejohn M, Yuen L, et al. HBV mutations in untreated HIV/HBV co-infection using genomic length sequencing[J]. *Virology. 2010;405(2):539–547. doi:10.1016/j.virol.2010.06.038*

14. Tamura K, Stecher G, Peterson D, et al. MEGA6: molecular evolutionary Genetics Analysis version 6.0.[J]. *Mol Biol Evol. 2013;30(12):2725–2729. doi:10.1093/molbev/mst197*

15. Tamura K, Peterson D, Peterson N, et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods[J]. *Mol Biol Evol. 2011;28(10):2731–2739. doi:10.1093/molbev/msr121*

16. Ali MS, Groenewold RHH, Beltser SV, et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review[J]. *J Clin Epidemiol. 2015;68(2):112–121. doi:10.1016/j.jclinepi.2014.08.011*

17. Maracy MR, Mostafaei S, Moghooife M, et al. Impact of HIV risk factors on survival in Iranian HIV-infected patients: A Bayesian approach to retrospective cohort[J]. *HIV AIDS Rev. 2017;2:100–106. doi:10.1141/hivar.2017.08117*

18. Cassino L, Laufer N, Salomon H, et al. Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBV–HCV coinfected patients: A 3-y retrospective study. *J Clin Virol. 2009;46(4):354–359. doi:10.1016/j.jcv.2009.09.015*

19. Mondal RK, Khatun M, Ghosh S, et al. Immune-driven adaptation of hepatitis B virus genotype D involves preferential alteration in B-cell epitopes and replicative attenuation—an insight from human immunodeficiency virus/hepatitis B virus coinfection. *Clin Microbiol Infect. 2015;21(7):710–711. doi:10.1016/j.cmi.2015.03.004*

20. Shen T. Hepatitis B virus genetic mutations and evolution in liver diseases[J]. *World J Gastroenterol. 2014;20(18):5435–5441. doi:10.3748/wjg.v20.i18.5435*

21. Moghooife M, Bokharaei-Salim F, Esghaei M, et al. microRNAs 29, 150, 155, 223 level and their relation to viral and immunological markers in HIV-1 infected naive patients[J]. *Future Virol. 2018;13(9):637–645. doi:10.2217/fvl-2018-0055*

22. Youssefpour S, Mostafaei S, Manesh PV. The assessment of selected miRNAs profile in HIV, HBV, HCV, HIV/HCV, HIV/HBV Co-infection and elite controllers for determination of biomarker. *Microb Pathog. 2020;147:104355. doi:10.1016/j.micpath.2020.104355*

23. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects[J]. *Antisod Redox Signal. 2013;18(17):2352–2363. doi:10.1089/red.2012.4834*

24. Hiraoka A, Horiike N, Akbar SMF, et al. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure[J]. *J Gastroenterol. 2005;40(1):52–56. doi:10.1007/s00535-004-1493-8*

25. Campbell JH, Hearps AC, Martin GE, et al. The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure[J]. *AIDS. 2014;28(15):2175–2187. doi:10.1097/QAD.0000000000000408*

26. Migita K, Sawakami-Kobayashi K, Maeda Y, et al. Interleukin-18 promoter polymorphisms and the disease progression of Hepatitis B virus-related liver disease[J]. *Transl Res. 2009;153(2):91–96. doi:10.1016/j.trsl.2008.11.008*

27. Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice[J]. *J Virol. 2002;76(21):10702–10707. doi:10.1128/JVI.76.21.10702-10707.2002*

28. Lee M-O, Choi Y-H, Shin E-C, et al. Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection[J]. *J Hepatol. 2002;37(3):380–386. doi:10.1016/S0168-8278(02)00181-2*

29. Li Y, Xie J, Wang H, et al. Elevated pre-treatment IL-18 level is associated with HBcAg seroconversion in HIV–HBV coinfected. *Antivir Ther. 2017;22(6):523–527. doi:10.3851/IMP3136*

30. Liu R, Guo J, Lu Y, et al. Changes in APRI and FIB-4 in HBcAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy[J]. *Clin Exp Med. 2019;19(3):309–320. doi:10.1007/s00238-019-00560-z*

31. Laffi G, Marra F, Gresele P, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation[J]. *Gastroenterology. 1992;103(2):641–646.*
Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/infection-and-drug-resistance-journal